Xenetic Biosciences, Inc. (XBIO) News

Xenetic Biosciences, Inc. (XBIO): $0.59

-0.06 (-9.80%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add XBIO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 468

in industry

Filter XBIO News Items

XBIO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

XBIO News Highlights

  • For XBIO, its 30 day story count is now at 2.
  • Over the past 26 days, the trend for XBIO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest XBIO News From Around the Web

Below are the latest news stories about XENETIC BIOSCIENCES INC that investors may wish to consider to help them evaluate XBIO as an investment opportunity.

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced that Jeffrey F. Eisenberg, Chief Executive Officer of Xenetic will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022.

Yahoo | September 7, 2022

Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

/Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today reported its financial results for the second quarter of 2022 and provided a business update.

Yahoo | August 12, 2022

Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard-to-treat cancers, and VolitionRx Limited (NYSE AMERICAN:VNRX) ("Volition"), a multi-national epigenetics company, today announced a research and development collaboration to develop Neutrophil Extracellular Traps ("NETs") targeted, adoptive cell therapies for the treatment of cancer.

Yahoo | August 2, 2022

Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study

* DNase-based oncology platform has the potential to improve outcomes of existing therapeutic agents in multiple solid tumor indications * Systemic DNase program initially targeting multi-billion-dollar indications including pancreatic carcinomaFRAMINGHAM, MA / ACCESSWIRE / July 7, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard-to-treat cancers, today announced i

Yahoo | July 7, 2022

JTC Team to Host Virtual Investor Innovation in Oncology Featuring Xenetic Biosciences

\- Live video webcast with moderated roundtable with members of the Xenetic leadership team and surgical oncology Key Opinion Leader, Allan Tsung, MD on Thursday, June 9th at 11:00 AM ET -FRENCHTOWN, NJ / ACCESSWIRE /June 2, 2022/JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor Innovation in Oncology Event Featuring Xenetic Biosciences on Thursday, June 9, 2022 at 11:00 AM ET. (NASDAQ:XBIO) is a biopharma

Yahoo | June 2, 2022

Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event

Live Video Webcast With Moderated Roundtable With Members of the Xenetic Leadership Team and Surgical Oncology Key Opinion Leader, Allan Tsung, MD on Thursday, June 9th at 11:00 AM ETFRAMINGHAM, MA / ACCESSWIRE / June 2, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced that it will participate in the Virtual Investor Inno

Yahoo | June 2, 2022

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference

Live Webcast Presentation on Wednesday, May 25th at 4:00 PM ETFRAMINGHAM, MA / ACCESSWIRE / May 18, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced that Jeffrey F.

Yahoo | May 18, 2022

Xenetic Biosciences (XBIO) Gets a Buy Rating from H.C. Wainwright

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Xenetic Biosciences (XBIO – Research Report), with a price target of $4.00. The company's shares closed last Thursday at $0.62, close to its 52-week low of $0.45. According to TipRanks.com, Pantginis has 0 stars on 0-5 stars ranking scale with an average return of -34.8% and a 10.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals. Currently, the analyst consensus on Xenetic Biosciences is a Moderate Buy with an average price target of $4.00.

Brian Anderson on TipRanks | May 13, 2022

Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

\- Company completed recent transaction to expand oncology pipeline with in-licensing of DNase based platform comprising multiple therapeutic modalities\- DNase based oncology platform has the potential to improve outcomes of existing therapeutic agents in multiple solid tumor indications\- Focusing resources on advancing DNase based oncology platform in locally advanced or metastatic solid tumors towards Phase 1 clinical development\- Ended the quarter with $16.2 million of cash to fund operati

Yahoo | May 12, 2022

H.C. Wainwright Maintains Their Buy Rating on Xenetic Biosciences (XBIO)

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Xenetic Biosciences (XBIO – Research Report) today and set a price target of $4.00. The company's shares closed last Friday at $0.74, close to its 52-week low of $0.70. According to TipRanks.com, Pantginis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -29.2% and a 16.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Xenetic Biosciences with a $4.00 average price target.

Brian Anderson on TipRanks | May 2, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5418 seconds.